Form 4: Disc Medicine CCO Receives Equity Grant

Disc Medicine's Chief Commercial Officer, Pamela Stephenson, was granted 17,000 restricted stock units and 25,500 stock options.

Summary

• Pamela Stephenson, Chief Commercial Officer of Disc Medicine, Inc. (IRON), was granted equity awards.
• The awards include 17,000 Restricted Stock Units (RSUs) and 25,500 stock options.
• The RSUs represent a contingent right to receive one share of common stock each, vesting annually in four 25% installments starting February 15, 2027.
• The stock options have an exercise price of $74.75 and vest in 48 equal monthly installments commencing on March 10, 2026, expiring on February 9, 2036.
• Following these transactions, Pamela Stephenson beneficially owns 86,529 shares of common stock and 25,500 stock options.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive event, reflecting standard executive compensation practices aimed at aligning management incentives with long-term company performance.

Positives

• Grants align the Chief Commercial Officer's interests with long-term shareholder value.
• Equity compensation serves as a retention tool for key executive talent.
• The awards provide a significant incentive for the Chief Commercial Officer to contribute to the company's growth and success.

Negatives

• No direct negatives are presented in this routine insider transaction report.

Risks

• No specific risks are mentioned in this Form 4 filing.

Future Outlook

This filing does not contain forward-looking statements or guidance regarding the company's future performance, beyond the vesting schedules of the granted equity.

Industry Context

StockSavvy.ai notes that equity grants to key executives like a Chief Commercial Officer are standard practice in the biotechnology and pharmaceutical industries. These grants are designed to incentivize long-term performance and align executive interests with shareholder value, particularly crucial in a sector characterized by long development cycles and significant R&D investment.

Comparison to Industry Standards

• Executive equity compensation packages, including RSUs and stock options, are a common component of total compensation across the biotech industry.
• While specific grant sizes vary based on company stage, market capitalization, and executive role, the structure observed here for Disc Medicine's CCO is consistent with typical practices for retaining and motivating senior leadership in growth-oriented life science companies.
• Similar structures are seen at companies like Moderna or BioNTech for their senior executives, albeit with different scales reflecting company size and market value.

Related Party Transactions

• This filing reports an equity grant to a company officer, which is a direct compensation event rather than a related party transaction in the typical sense of a separate business dealing.

Stakeholder Impact

• Shareholders: Potential minor dilution from the issuance of new shares upon vesting/exercise, but also improved alignment of executive incentives with long-term shareholder value.
• Employees: May signal a stable compensation strategy for key personnel, potentially boosting morale and retention.

Next Steps

• Vesting of 17,000 Restricted Stock Units annually in four 25% installments commencing on February 15, 2027.
• Vesting of 25,500 stock options in 48 equal monthly installments commencing on March 10, 2026.

Key Dates

Keywords

Disc Medicine, IRON, Pamela Stephenson, Chief Commercial Officer, Form 4, Insider Transaction, Restricted Stock Units, RSU, Stock Options, Equity Grant, Executive Compensation